Insuman Comb 30 Solostar (Insulin Human)

Insulin human mimics the body’s natural insulin by binding to insulin receptors on muscle, fat and liver cells. This activates intracellular pathways that increase glucose uptake, reduce hepatic glucose production, and promote storage of glucose as glycogen, thereby lowering blood glucose concentrations.

The dose is individualized by the prescribing healthcare professional based on the patient’s blood glucose readings, carbohydrate intake, activity level, and overall treatment goals. Patients should follow the prescriber’s instructions and regularly monitor glucose to guide any dose adjustments.

Data on insulin human use in pregnancy and lactation are limited. It may be used when the expected benefit to the mother outweighs potential risks to the fetus or infant. Women who are pregnant, planning pregnancy, or breastfeeding should discuss use with their healthcare provider.

To place an order, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain handling) and necessary import documentation.

Insuman Comb 30 Solostar contains human insulin rather than a rapid‑acting analogue. It offers a blend of short‑acting and protamine‑bound insulin, providing both mealtime coverage and basal effect in a single injection. Compared with rapid‑acting analogues, it may have a slightly slower onset but can simplify dosing for some patients.

Store the pen at 2‑8 °C (refrigerated) and protect it from direct light. Do not freeze or shake the pen. Once in use, it may be kept at room temperature (up to 25 °C) for a limited period as indicated in the product insert, but should be discarded after the recommended in‑use time.

The medication is delivered subcutaneously using the prefilled pen. The pen is primed according to the manufacturer’s instructions, the appropriate dose is selected by turning the dose selector, and the needle is inserted into the subcutaneous tissue of the abdomen, thigh or upper arm before injection.

The most serious risks include severe hypoglycaemia, which can cause loss of consciousness or seizures, and rare allergic reactions such as anaphylaxis. Patients should be educated to recognize early signs of low blood sugar and to seek immediate medical attention if a severe reaction occurs.

Individuals with a known hypersensitivity to human insulin or any excipients in the formulation should avoid this product. It is also contraindicated in patients experiencing hypoglycaemia unawareness or those for whom insulin therapy is not indicated. Clinical judgment is required for patients with certain medical conditions, such as severe renal impairment.